secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193125-23-276676
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Q3 JELMYTO revenue $20.9M (+30% YoY); FDA agrees to rolling NDA for UGN-102
--------------------------------------------------------------------------------

- JELMYTO net product revenue $20.9M in Q3 2023, up ~30% from $16.1M in Q3 2022.
- FDA agreed to rolling NDA for UGN-102 in LG-IR-NMIBC starting Jan 2024; ENVISION trial showed 79.2% CRR at 3 months.
- Net loss improved to $21.9M ($0.68/sh) from $25.8M ($1.13/sh) in Q3 2022.
- Cash and marketable securities $153.9M as of Sep 30, 2023; FY 2023 revenue guidance reiterated at $76-86M.
- ATLAS trial met primary endpoint; 55% reduction in risk of recurrence/progression/death.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523276676/0001193125-23-276676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523276676/d437259d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-276676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer